Deep Medicine Acquisition - Tradeable Rights - Oct 2026 Overview

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 Cost of Revenue

Cost of Revenue analysis for DMAQR.

Quarterly Cost of Revenue

$2.34M

↑ 35.4% YoY

As of Mar 31, 2026

Annual Cost of Revenue (TTM)

$9.97M

↑ 37.3% YoY

Trailing 12 months ending Mar 31, 2026

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin